Top 5 Stocks to Buy Now
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free AGY Stock Alerts

Allergy Therapeutics (AGY) Competitors

Allergy Therapeutics logo
GBX 7.50 +0.24 (+3.31%)
As of 05:45 AM Eastern
Compare

AGY vs. INDV, HCM, AMYT, APH, and ANCR

Should you buy Allergy Therapeutics stock or one of its competitors? MarketBeat compares Allergy Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Allergy Therapeutics include Indivior (INDV), HUTCHMED (HCM), Amryt Pharma (AMYT), Alliance Pharma (APH), and Animalcare Group (ANCR). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does Allergy Therapeutics compare to Indivior?

Indivior (LON:INDV) and Allergy Therapeutics (LON:AGY) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Indivior has a net margin of 14.30% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Indivior's return on equity.

Company Net Margins Return on Equity Return on Assets
Indivior14.30% -41.70% 2.37%
Allergy Therapeutics -85.46%409.00%-34.76%

86.0% of Indivior shares are held by institutional investors. Comparatively, 0.0% of Allergy Therapeutics shares are held by institutional investors. 3.4% of Indivior shares are held by company insiders. Comparatively, 3.5% of Allergy Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Indivior has higher revenue and earnings than Allergy Therapeutics. Indivior is trading at a lower price-to-earnings ratio than Allergy Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Indivior£1.40B1.38-£2.36M-£1.21N/A
Allergy Therapeutics£57.29M8.29-£52.59M-£0.97N/A

In the previous week, Indivior had 1 more articles in the media than Allergy Therapeutics. MarketBeat recorded 1 mentions for Indivior and 0 mentions for Allergy Therapeutics. Indivior's average media sentiment score of 0.75 beat Allergy Therapeutics' score of 0.00 indicating that Indivior is being referred to more favorably in the media.

Company Overall Sentiment
Indivior Positive
Allergy Therapeutics Neutral

Indivior has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market. Comparatively, Allergy Therapeutics has a beta of 0.849, meaning that its stock price is 15% less volatile than the broader market.

Summary

Indivior beats Allergy Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Allergy Therapeutics compare to HUTCHMED?

Allergy Therapeutics (LON:AGY) and HUTCHMED (LON:HCM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

0.0% of Allergy Therapeutics shares are held by institutional investors. Comparatively, 20.4% of HUTCHMED shares are held by institutional investors. 3.5% of Allergy Therapeutics shares are held by company insiders. Comparatively, 2.8% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

HUTCHMED has a net margin of 104.77% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat HUTCHMED's return on equity.

Company Net Margins Return on Equity Return on Assets
Allergy Therapeutics-85.46% 409.00% -34.76%
HUTCHMED 104.77%41.38%-5.90%

Allergy Therapeutics has a beta of 0.849, indicating that its stock price is 15% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.368, indicating that its stock price is 63% less volatile than the broader market.

In the previous week, Allergy Therapeutics' average media sentiment score of 0.00 equaled HUTCHMED'saverage media sentiment score.

Company Overall Sentiment
Allergy Therapeutics Neutral
HUTCHMED Neutral

Allergy Therapeutics has higher earnings, but lower revenue than HUTCHMED. Allergy Therapeutics is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allergy Therapeutics£57.29M8.29-£52.59M-£0.97N/A
HUTCHMED£548.51M2.48-£52.98M£53.002.98

Summary

HUTCHMED beats Allergy Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Allergy Therapeutics compare to Amryt Pharma?

Allergy Therapeutics (LON:AGY) and Amryt Pharma (LON:AMYT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

In the previous week, Allergy Therapeutics' average media sentiment score of 0.00 equaled Amryt Pharma'saverage media sentiment score.

Company Overall Sentiment
Allergy Therapeutics Neutral
Amryt Pharma Neutral

Amryt Pharma has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Amryt Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allergy Therapeutics£57.29M8.29-£52.59M-£0.97N/A
Amryt Pharma£210.24M0.00N/A-£33.00N/A

Amryt Pharma has a net margin of 0.00% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Amryt Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Allergy Therapeutics-85.46% 409.00% -34.76%
Amryt Pharma N/A N/A N/A

0.0% of Allergy Therapeutics shares are held by institutional investors. 3.5% of Allergy Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Allergy Therapeutics and Amryt Pharma tied by winning 4 of the 8 factors compared between the two stocks.

How does Allergy Therapeutics compare to Alliance Pharma?

Allergy Therapeutics (LON:AGY) and Alliance Pharma (LON:APH) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

Alliance Pharma has higher revenue and earnings than Allergy Therapeutics. Alliance Pharma is trading at a lower price-to-earnings ratio than Allergy Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allergy Therapeutics£57.29M8.29-£52.59M-£0.97N/A
Alliance Pharma£183.50M1.91-£33.65M-£6.20N/A

Alliance Pharma has a net margin of -6.00% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Alliance Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Allergy Therapeutics-85.46% 409.00% -34.76%
Alliance Pharma -6.00%-5.04%5.98%

0.0% of Allergy Therapeutics shares are held by institutional investors. Comparatively, 66.3% of Alliance Pharma shares are held by institutional investors. 3.5% of Allergy Therapeutics shares are held by insiders. Comparatively, 12.0% of Alliance Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Allergy Therapeutics' average media sentiment score of 0.00 equaled Alliance Pharma'saverage media sentiment score.

Company Overall Sentiment
Allergy Therapeutics Neutral
Alliance Pharma Neutral

Allergy Therapeutics has a beta of 0.849, meaning that its share price is 15% less volatile than the broader market. Comparatively, Alliance Pharma has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

Summary

Alliance Pharma beats Allergy Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Allergy Therapeutics compare to Animalcare Group?

Allergy Therapeutics (LON:AGY) and Animalcare Group (LON:ANCR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

In the previous week, Allergy Therapeutics' average media sentiment score of 0.00 equaled Animalcare Group'saverage media sentiment score.

Company Overall Sentiment
Allergy Therapeutics Neutral
Animalcare Group Neutral

Allergy Therapeutics has a beta of 0.849, meaning that its share price is 15% less volatile than the broader market. Comparatively, Animalcare Group has a beta of 0.663, meaning that its share price is 34% less volatile than the broader market.

Animalcare Group has a net margin of 5.70% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Animalcare Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Allergy Therapeutics-85.46% 409.00% -34.76%
Animalcare Group 5.70%4.46%2.97%

Animalcare Group has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Animalcare Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allergy Therapeutics£57.29M8.29-£52.59M-£0.97N/A
Animalcare Group£89.11M2.58£36.55M£7.3045.53

0.0% of Allergy Therapeutics shares are owned by institutional investors. Comparatively, 14.3% of Animalcare Group shares are owned by institutional investors. 3.5% of Allergy Therapeutics shares are owned by insiders. Comparatively, 30.1% of Animalcare Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Animalcare Group beats Allergy Therapeutics on 8 of the 11 factors compared between the two stocks.

Get Allergy Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AGY vs. The Competition

Export
MetricAllergy TherapeuticsDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£474.94M£2.35B£6.47B£2.78B
Dividend Yield8.33%2.95%2.68%6.16%
P/E Ratio-7.734.9424.71365.72
Price / Sales8.291,653.15521.5186,253.69
Price / Cash3.6610.1827.9227.85
Price / Book76.0011.0110.827.92
Net Income-£52.59M£20.27B£3.56B£5.89B
7 Day PerformanceN/A-0.80%1.67%-0.87%
1 Month Performance-16.67%-1.04%0.43%-0.76%
1 Year Performance7.14%12.97%32.84%70.67%

Allergy Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AGY
Allergy Therapeutics
N/AGBX 7.50
+3.3%		N/A+5.2%£474.94M£57.29MN/A612
INDV
Indivior
N/AGBX 1,238
+1.6%		N/A+18.2%£1.93B£1.40BN/A1,000
HCM
HUTCHMED
N/AGBX 160
-3.0%		N/A-28.5%£1.38B£548.51M3.021,760
AMYT
Amryt Pharma
N/AN/AN/AN/A£457.11M£210.24MN/A290
APH
Alliance Pharma
N/AGBX 64.70
flat		N/AN/A£350.32M£183.50MN/A91,000

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:AGY) was last updated on 6/23/2026 by MarketBeat.com Staff.
From Our Partners
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
Porter flew 3,300 miles to investigate this system
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel